WO2016197357A1 - CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA - Google Patents

CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA Download PDF

Info

Publication number
WO2016197357A1
WO2016197357A1 PCT/CN2015/081229 CN2015081229W WO2016197357A1 WO 2016197357 A1 WO2016197357 A1 WO 2016197357A1 CN 2015081229 W CN2015081229 W CN 2015081229W WO 2016197357 A1 WO2016197357 A1 WO 2016197357A1
Authority
WO
WIPO (PCT)
Prior art keywords
sla
gene
sequence
sgrna
target sequence
Prior art date
Application number
PCT/CN2015/081229
Other languages
English (en)
French (fr)
Inventor
蔡志明
牟丽莎
张军方
谢崇伟
陆赢
高汉超
刘璐
陈鹏飞
Original Assignee
深圳市第二人民医院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳市第二人民医院 filed Critical 深圳市第二人民医院
Priority to PCT/CN2015/081229 priority Critical patent/WO2016197357A1/zh
Priority to CN201580000474.9A priority patent/CN106414740A/zh
Publication of WO2016197357A1 publication Critical patent/WO2016197357A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Definitions

  • the invention relates to the field of genetic engineering technology, in particular to the field of gene knockout technology, in particular to a method for specifically knocking out a porcine SLA-3 gene by CRISPR-Cas9 and an sgRNA for specifically targeting the SLA-3 gene.
  • Organ transplantation is the most effective treatment for organ failure diseases. To date, nearly one million patients worldwide have survived through organ transplantation. With the aging of the population and advances in medical technology, more and more patients need organ transplant surgery, but the shortage of donor organs severely restricts the development of organ transplant surgery. Taking kidney transplantation as an example, there are as many as 300,000 patients who need kidney transplantation every year in China, and no more than 10,000 donated kidneys for transplantation. Most of the patients die from kidney failure. Relying on post-mortem organ donation can no longer meet the needs of organ transplantation. Genetic engineering of other species to provide organs suitable for human transplantation has become the main way to address the shortage of human donor organs.
  • Swine leukocyte antigen (SLA) class I molecules are important functional genes that represent the genetic characteristics of gene molecules. They are called SLA-1 (PD1), SLA-2 (PD14), and SLA-3 (PD7), respectively, and are also called SLA-C, SLA-B, and SLA-A, respectively.
  • SLA-1 PD1
  • SLA-2 PD14
  • SLA-3 PD7
  • SLA-C SLA-B
  • SLA-A Swine leukocyte antigen
  • the classical SIJA gene is mainly expressed in the immune system and the digestive system, especially in the immune system.
  • the tissues such as the spleen, thymus, and bronchial lymph nodes are rich in immune cells.
  • Human CD4 T cells recognize porcine heterologous antigens through an indirect antigen-presenting pathway and are primarily recognized by SLA class I molecules.
  • common gene knockout techniques include homologous recombination (HR) technology, Transcription Activator-Like Effector Nuclease (TALEN) technology, Zinc-Finger Nuclease (ZFN) Technology and the recently developed Law Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) technique.
  • HR homologous recombination
  • TALEN Transcription Activator-Like Effector Nuclease
  • ZFN Zinc-Finger Nuclease
  • CRISPR Law Clustered Regularly Interspaced Short Palindromic Repeat Due to the inefficient recombination of HR technology (efficiency is only about 10 -6 ), the screening of mutants is very time consuming and inefficient, and has gradually been replaced.
  • the cutting efficiency of TALEN technology and ZFN technology can generally reach 20%, but all need to build protein modules that can recognize specific sequences, and the preliminary work is cumbersome and time consuming.
  • the module design of ZFN technology is complex and has a high off
  • CRISPR is an acquired immune system derived from prokaryotes that performs a function of interfering functions consisting of protein Cas and CRISPR-RNA (crRNA).
  • Cas9 targeted cleavage of DNA is achieved by the principle of complementary recognition of two small RNAs, cryRNA (CRISPR RNA) and tracrRNA (trans-activating crRNA), to target sequences.
  • CRISPR RNA cryRNA
  • tracrRNA trans-activating crRNA
  • the two small RNAs have now been fused into an RNA strand, abbreviated as sgRNA (single guide RNA), which recognizes specific gene sequences and directs Cas9 protein for cleavage.
  • sgRNA single guide RNA
  • the CRISPR technology is simple in operation, high in screening efficiency, and capable of achieving accurate targeted cutting. Therefore, knocking out the SLA-3 gene by CRISPR technology can greatly improve the screening efficiency of Neu5Gc-deficient cells and genetically engineered pigs.
  • the key technical challenge of this path is to design and prepare precisely targeted sgRNAs, because the targeting accuracy of genes is highly dependent on sgRNA target sequences, and the successful design of precisely targeted sgRNAs becomes a key technical issue for knocking out target genes.
  • the present invention is intended to solve this technical problem and thereby provide a solid basis for knocking out the SLA-3 gene.
  • the object of the present invention is to provide a method for CRISPR-Cas9 specific knockdown of the porcine SLA-3 gene and an sgRNA for specifically targeting the SLA-3 gene.
  • the present invention provides an sgRNA for specifically targeting an SLA-3 gene in a CRISPR-Cas9 specific knockout porcine SLA-3 gene, the sgRNA having the following characteristics:
  • the target sequence of the sgRNA on the SLA-3 gene conforms to the sequence alignment rule of 5'-N(20)NGG-3', wherein N(20) represents 20 contiguous bases, wherein each N represents A Or T or C or G, a rule-compliant target sequence may be located in the sense strand or the antisense strand;
  • the target sequence of the sgRNA on the SLA-3 gene is located in the 5 exon coding regions at the N-terminus of the SLA-3 gene, or the major portion of the sequence is located at 5 N-terminal exons of the SLA-3 gene, and the rest Partially crossing the boundary with adjacent introns, located adjacent to the intron;
  • the target sequence of the sgRNA on the SLA-3 gene is unique.
  • the above target sequence is the sequence shown by any one of SEQ ID NOS: 1 to 115 in the Sequence Listing.
  • the above target sequence is the sequence shown by SEQ ID NO: 4, 5 or 12 in the Sequence Listing.
  • the present invention provides a method for CRISPR-Cas9 specific knockout of a porcine SLA-3 gene, the method comprising the steps of:
  • the 5'-end of the target sequence of the sgRNA described in the first aspect is added to the sequence for forming the cohesive end, and the forward oligonucleotide sequence is synthesized; the target sequence of the sgRNA described in the first aspect
  • the opposite ends of the corresponding complementary sequences are added with appropriate sequences for forming sticky ends, and the reverse oligonucleotide sequence is synthesized; the synthesized forward oligonucleotide sequence is annealed to the reverse oligonucleotide sequence, To form a double-stranded oligonucleotide having a sticky end;
  • the above expression vector is a vector of the sequence shown by SEQ ID NO: 116 in the Sequence Listing.
  • the above method comprises the following steps:
  • a forward oligonucleotide sequence is synthesized by adding a CACCG sequence to the 5'-end of the target sequence of the sgRNA of the first aspect; the target sequence corresponding to the target sequence of the sgRNA of the first aspect is The 5'-end plus the AAAC sequence and the 3'-end plus C, the reverse oligonucleotide sequence is synthesized; the synthesized forward oligonucleotide sequence is annealed and renatured with the reverse oligonucleotide sequence, Forming a double-stranded oligonucleotide having a cohesive terminus;
  • the above double-stranded oligonucleotide is ligated into a linearized vector obtained by digesting the expression vector lentiCRISPR v2 of the sequence shown by SEQ ID NO: 116 in the sequence listing by BsmB I restriction endonuclease to obtain a sgRNA.
  • the recombinant expression vector lentiCRISPR v2-SLA-3 of the oligonucleotide was transformed into competent bacteria, and the correct positive clone was screened, and the positive clone was shaken and the plasmid was extracted;
  • the above packaging plasmid is plasmid pLP1, plasmid pLP2 and plasmid pLP/VSVG; and the above packaging cell line is HEK293T cells.
  • the above target cells are porcine PIEC cells.
  • the gene fragment comprising the target sequence is amplified by using the genomic DNA as a template, and the knockdown of the SLA-3 gene is determined by denaturation, renaturation and enzymatic cleavage, specifically:
  • Genomic DNA of a type cell (a) using the genomic DNA of the target cell infected with the virus as a template, and using the upstream and downstream primers of the SLA-3 gene to amplify the SLA-3 gene fragment containing the target sequence of the above sgRNA, and simultaneously amplifying the uninfected virus with the same primer.
  • Genomic DNA of a type cell (a) using the genomic DNA of the target cell infected with the virus as a template, and using the upstream and downstream primers of the SLA-3 gene to amplify the SLA-3 gene fragment containing the target sequence of the above sgRNA, and simultaneously amplifying the uninfected virus with the same primer.
  • the present invention provides a recombinant expression vector lentiCRISPR v2-SLA-3 used in a method of CRISPR-Cas9 specific knockout of a porcine SLA-3 gene, the sequence of the backbone vector of the recombinant expression vector being as SEQ ID NO: 116 in the Sequence Listing;
  • the target sequence carried, such as the target sequence of the sgRNA of the first aspect is preferably the target sequence set forth in SEQ ID NO: 4, 5 or 12 of the Sequence Listing.
  • the present invention provides the sgRNA according to the first aspect or the recombinant expression vector lentiCRISPR v2-SLA-3 of the third aspect, wherein the CRISPR-Cas9 specific knockout porcine SLA-3 gene method Use in.
  • the present invention specifically knocks out the porcine SLA-3 gene for CRISPR-Cas9, successfully finds sgRNA that specifically targets the SLA-3 gene, and uses the sgRNA of the present invention for the CRISPR-Cas9 specific knockout porcine SLA-3 gene
  • the pig SLA-3 gene can be knocked out quickly, accurately, efficiently and specifically, and the technical problem of constructing the SLA-3 gene knockout pig with long cycle and high cost is effectively solved.
  • Figure 1 is a plasmid map of the vector plasmid lentiCRISPR v2 used in the examples of the present invention
  • Figure 2 is a plasmid map of the packaging plasmid pLP1 used in the embodiment of the present invention
  • Figure 3 is a plasmid map of the packaging plasmid pLP2 used in the examples of the present invention.
  • Figure 4 is a plasmid map of the packaging plasmid pLP/VSVG used in the examples of the present invention.
  • FIG. 5 is a diagram showing the results of electrophoresis detection of the gene knock-out effect of the target sequence of the enzyme digestion in the embodiment of the present invention, wherein M represents DNA Marker, and 4, 5, and 12 represent No. 4, No. 5, and No. 12 in Table 1, respectively.
  • the target cleavage effect of the target sequence on the SLA-3 gene, WT indicates the result of the Cruise product digestion test of the PCR product of the wild-type cells not subjected to viral infection and Cas9 cleavage, and the arrow indicates the small fragment obtained by cutting with the Cruiser enzyme.
  • test materials and reagents involved in the following examples lentiCRISPR v2 plasmid was purchased from Addgene, packaging plasmids pLP1, pLP2 and pLP/VSVG were purchased from Invitrogen, and packaging cell line HEK293T cells were purchased from the American Model Culture Collection (ATCC).
  • PIEC cells were purchased from the Chinese Academy of Sciences cell bank, DMEM medium, Opti-MEM medium and fetal bovine serum FBS were purchased from Gibco, and Lipofectamine 2000 was purchased from Invitrogen.
  • a suitable 20 bp oligonucleotide sequence was searched for as a target sequence in the exon region of the SLA-3 gene.
  • the above target sequence and complementary sequence are separately added to the linker to form a forward oligonucleotide sequence and a reverse oligonucleotide sequence.
  • the above double-stranded DNA fragment was constructed into a vector of interest (e.g., lenti CRISPR V2, the plasmid map of which is shown in Figure 1) to form a lentiviral CRISPR vector such as lenti CRISPR SP2-SLA-3.
  • a vector of interest e.g., lenti CRISPR V2, the plasmid map of which is shown in Figure 1
  • lentiviral CRISPR vector such as lenti CRISPR SP2-SLA-3.
  • a CRISPR pseudotyped lentivirus expressing SLA-3 sgRNA was produced using a packaging plasmid, a packaging cell line, and a lentiviral CRISPR vector.
  • a pseudotype lentivirus such as lentiCRISPR v2-SLA-3 is added to the cell culture medium of interest for infection and further culture.
  • the target cells are collected, and the gene fragment containing the target sequence is amplified by using genomic DNA as a template, and the knockdown of the SLA-3 gene is determined by denaturation, renaturation and restriction enzyme digestion.
  • a number of single cell derived cell lines are isolated by dilution and monoclonal culture.
  • the target sequence determines the targeting specificity of the sgRNA and the efficiency of the Cas9-cleaving gene of interest. Therefore, efficient and specific target sequence selection and design are prerequisites for the construction of sgRNA expression vectors.
  • N(20) represents 20 contiguous bases, wherein each N represents A Or T or C or G, a rule-compliant target sequence may be located in the sense strand or the antisense strand;
  • the CACCG sequence was added to the 5'-end of the above N(20) target sequence to form a forward oligonucleotide sequence according to the characteristics of the lenti CRISPR SP2 plasmid:
  • the forward oligonucleotide sequence and the reverse oligonucleotide sequence can be complementary to form a double-stranded DNA fragment having a sticky end:
  • Example 2 sgRNA expression vector for constructing SLA-3 gene
  • Oligonucleotide sequences can be specifically synthesized by commercial companies (such as Invitrogen) according to the sequences provided. This example and the following examples investigate the knockdown effect of the target sequence shown in the sequences No. 4, No. 5 and No. 12 listed in Table 1 on the SLA-3 gene.
  • the forward oligonucleotide sequence and the reverse oligonucleotide sequence corresponding to the target sequence No. 4 are as follows:
  • the forward oligonucleotide sequence and the reverse oligonucleotide sequence corresponding to the target sequence No. 5 are as follows:
  • the forward oligonucleotide sequence and the reverse oligonucleotide sequence corresponding to the target sequence No. 12 are as follows:
  • the corresponding forward and reverse oligonucleotide sequences are annealed and renatured to form a double-stranded DNA fragment having sticky ends.
  • the reaction system (20 ⁇ L) is as follows:
  • the above reaction system was placed in a PCR machine, and the reaction was carried out in accordance with the following procedure.
  • the target vector lentiCRISPR v2 plasmid (the sequence of which is shown in SEQ ID NO: 116 in the Sequence Listing) was digested with BsmB I restriction endonuclease.
  • the digestion reaction system was placed at 37 ° C for 4 h.
  • the digestion mixture was separated by agarose gel electrophoresis, and the vector fragment (about 12 kb) was selected for cleavage and recovered by a DNA gel recovery column.
  • the double-stranded DNA fragment obtained by renaturation is linked with the recovered vector fragment, and is prepared according to the following reaction system:
  • Double-stranded DNA fragment 200ng
  • the ligation mixture was reacted at 25 ° C for 2 h.
  • the ligation mixture was transformed into E. coli DH5 ⁇ strain: 100 ⁇ L of E. coli DH5 ⁇ competent cells were added to the ligation mixture, and incubated on ice for 30 min; the mixture was placed in a 42 ° C water bath, heat shocked for 90 s, and then placed on ice to cool; Add 100 ⁇ L of LB medium and incubate at 37 ° C for 20 min on a shaker; The mixture was coated on an Amp LB plate and incubated at 37 ° C for 14 h.
  • Example 3 obtaining a pseudotype lentivirus expressing SLA-3sgRNA
  • Amplify and extract the packaging plasmids pLP1, pLP2 and pLP/VSVG (purchased from Invitrogen, the maps are shown in Figure 2, Figure 3 and Figure 4, respectively); amplify and extract the vector plasmid lentiCRISPR v2-SLA-3; culture Packaging cell line HEK293T cells (purchased from ATCC); DMEM medium, Opti-MEM medium and fetal bovine serum FBS (purchased from Gibco); Lipofectamine 2000 (purchased from Invitrogen); HEK293T cells cultured at 37 ° C with 5% CO 2 In the culture environment, the medium was DMEM medium containing 10% FBS.
  • Formulation of Mixture 1 comprising:
  • Opti-MEM 500 ⁇ L.
  • Formulation of Mixture 2 comprising:
  • Opti-MEM 500 ⁇ L.
  • mixture 1 and mixture 2 were mixed to form a transfection mixture and allowed to stand for 20 min.
  • the HEK293T medium was changed to serum-free DMEM medium, and the transfection mixture was added. After incubation at 37 ° C for 8 hours, the cells were replaced with 20% FBS DMEM medium, and the culture was continued.
  • Example 4 infecting the target cell and detecting the knockout effect of the target sequence
  • PIEC porcine hip arterial vascular endothelial cells
  • DMEM medium and fetal bovine serum FBS purchased from Gibco
  • lentiCRISPR v2 of different target sequences sequence 4, sequence 5 and sequence 12
  • SLA-3 pseudotype lentivirus PIEC cells were cultured in a 37 ° C culture environment containing 5% CO 2 in DMEM medium containing 10% FBS.
  • Day 1 Passage cells of interest to 6-well plates at approximately 20% fusion density. Each virus requires a 6-well and requires an efficiency of 6 wells.
  • Uninfected efficacious control cells should all be apoptotic (>95%) under the action of puromycin.
  • the infection efficiency of cells can be determined, and the infection efficiency of 90% or more can be achieved (apoptosis rate ⁇ 10%). If necessary, the virus supernatant can be concentrated or diluted to be infected to achieve appropriate infection efficiency.
  • GGGCAGGAAACAAGGGAGGG (SEQ ID NO: 124).
  • the amplified fragment of interest contains the sgRNA target sequence and is 487 bp in size.
  • the position of the target sequence to both ends of the fragment is not less than 100 bp.
  • the amplification reaction system (20 ⁇ L) was as follows:
  • the above reaction system was prepared, placed in a PCR machine, and reacted according to the following procedure.
  • the second to fourth steps are repeated for 35 cycles.
  • the purified DNA fragments are separately denatured and renatured to form hybrid DNA molecules (including mutant samples and wild-type samples).
  • the reaction system is as follows:
  • Genomic PCR fragment 200ng
  • reaction buffer 2 ⁇ L
  • the reaction system has a total of 9 ⁇ L
  • the above reaction system was prepared, placed in a PCR machine, and reacted according to the following procedure.
  • the renatured hybrid DNA (including the mutant sample and the wild type sample) was cleaved with a Cruiser enzyme, and 1 ⁇ L of the Cruiser enzyme was added to the denatured and renatured reaction mixture, and incubated at 45 ° C for 20 min.
  • the digested DNA fragment was subjected to electrophoresis on a 2% agarose gel, 100 V, 25 min.
  • the cutting condition of the target fragment is determined, and the gene knocking effect of the target sequence is judged.
  • mutant DNA The cleavage recognition of mutant DNA is based on the principle that infected cells express sgRNA and Cas9. Genomic DNA, if sgRNA-mediated Cas9 protein-targeted cleavage, is introduced to introduce mutations near the cleavage site (wild-type becomes mutant). Since the wild type and the mutant sequence do not match at this position, the hybrid molecule in which the wild type DNA amplified by the template and the mutant DNA undergoes renaturation will generate a local loop structure. The latter can be recognized and cleaved by the Cruiser enzyme, resulting in the hybrid DNA molecule being cleaved into small fragments.
  • sequence 4 sequence 5 and sequence 12 were able to effectively target the SLA-3 gene to produce a cleavage, and thus a small fragment was detected.
  • Existence indicating that sequence 4, sequence 5 and sequence 12 are capable of specifically knocking out the target sequence of the porcine SLA-3 gene by CRISPR-Cas9.
  • the partially infected cell population was passaged, and 100 single cells were transferred to a 10 cm dish for culture.
  • the annealed hybrid DNA was cleaved with a Cruiser enzyme and incubated at 45 ° C for 20 min.
  • the lentiCRISPR v2-SLA-3 pseudotyped lentivirus infection target cell based on the target sequence shown in SEQ ID NO: 12, 20 monoclonal clones randomly selected from 100 single cells were detected by Cruiser enzyme electrophoresis, and 18 of them were monoclonal. It can detect small fragments, indicating that gene knockout occurs, and the knockout efficiency can reach more than 90%, indicating that the target sequence shown in sequence 12 has a high target for knocking out the SLA-3 gene.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

提供了一种利用CRISPR-CaS9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA。特异性靶向SLA-3基因的sgRNA在SLA-3基因上的靶序列位于SLA-3基因的N端的5个外显子编码区域与相邻内含子的交界处。

Description

CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA 技术领域
本发明涉及基因工程技术领域，尤其涉及基因敲除技术领域，具体涉及CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA。
背景技术
器官移植是治疗器官衰竭疾病最有效的治疗手段。迄今为止，全球已有近百万的患者通过器官移植而延续生命。随着人口老龄化及医疗技术的进步，需要进行器官移植手术的病人越来越多，但供体器官的短缺严重制约了器官移植手术的开展。以肾脏移植为例，我国每年需要进行肾移植的患者多达30万，而可用于移植的捐献肾脏不超过1万例，大部分患者死于肾衰竭。依靠死后器官捐献已不能满足器官移植的需要。通过基因工程改造其他物种，以提供合适于人体移植的器官，成为解决人类供体器官短缺问题的主要途径。
目前，根据生物安全性、生理功能指标、经济性及稀有物种保护等多方面评价，猪成为了最为理想的异种器官来源。但猪和人之间存在巨大的差异，直接将猪的器官移植到人会产生强烈的免疫排斥反应。因此，通过基因工程对猪进行改造，以产生适合于人体移植的器官，成为异种移植的终极目标。
猪白细胞抗原(swine leukocyte antigen，SLA)I类分子是代表基因分子遗传特征的重要功能基因。分别称为SLA-1(PD1)、SLA-2(PD14)和SLA-3(PD7)，也分别称为SLA-C、SLA-B和SLA-A。经典的SIJA基因主要高表达于免疫系统和消化系统，尤其在免疫系统中，脾、胸腺、支气管淋巴结等组织富含免疫细胞。人CD4 T细胞通过间接的抗原递呈途径识别猪的异种抗原，且主要为SLA I类分子所识别。因此，需要消除猪细胞表面的SLA I类分子以减少异种供体器官的免疫原性。而准确高效的敲除猪SLA-3基因，是消除SLA I类分子引起的免疫排斥的关键步骤。
目前，常见的基因敲除技术包括同源重组(Homologus Recombination，HR)技术、类转录激活效应子核酸酶(Transcription Activator-Like Effector Nuclease，TALEN)技术、锌指核酸酶(Zinc-Finger Nuclease，ZFN)技术以及最近发展的规律成簇间隔短回文重复(Clustered Regularly Interspaced Short Palindromic  Repeat，CRISPR)技术。HR技术由于重组效率低下(效率大约只有10-6)，对突变体的筛选工作非常耗时和低效，已逐渐被取代。TALEN技术和ZFN技术的切割效率一般能达到20％，但都需要构建可以识别特定序列的蛋白质模块，前期工作繁琐费时。ZFN技术的模块设计较为复杂且有较高的脱靶率，其应用有限。
CRISPR是一种源于原核生物的后天免疫系统，该系统执行干扰功能的复合物由蛋白质Cas和CRISPR-RNA(crRNA)组成。目前该系统已发现有三种类型，其中第二类Cas9系统组成简单，已被积极应用于基因工程领域。Cas9靶向切割DNA是通过两种小RNA——crRNA(CRISPR RNA)和tracrRNA(trans-activating crRNA)与靶序列互补识别的原理实现的。现在已经将两种小RNA融合成一条RNA链，简称sgRNA(single guide RNA)，能够识别特定的基因序列，引导Cas9蛋白进行切割。在真核生物中，DNA被切断后发生非同源重组末端连接，造成移码突变，最终导致基因功能性敲除。
相比于上述3种技术，CRISPR技术操作简单、筛选效率高，能够实现精确的靶向切割。因此，通过CRISPR技术敲除SLA-3基因能够极大地提高Neu5Gc缺失细胞及基因工程猪的筛选效率。但是该路径的关键技术难题是设计并制备精确靶向的sgRNA，因为基因的靶向精确度高度依赖于sgRNA靶序列，能否成功设计出精确靶向的sgRNA成为敲除目的基因的关键技术问题，本发明意在解决该技术问题从而为敲除SLA-3基因提供坚实的基础。
发明内容
本发明的目的在于提供CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA。
根据本发明的第一方面，本发明提供在CRISPR-Cas9特异性敲除猪SLA-3基因中用于特异性靶向SLA-3基因的sgRNA，该sgRNA具有以下特点：
(1)该sgRNA在SLA-3基因上的靶序列符合5’-N(20)NGG-3’的序列排列规则，其中N(20)表示20个连续的碱基，其中每个N表示A或T或C或G，符合规则的靶序列可以位于正义链或反义链；
(2)该sgRNA在SLA-3基因上的靶序列位于SLA-3基因的N端的5个外显子编码区，或序列的主要部分位于SLA-3基因的N端的5个外显子，其余部分跨越与相邻内含子的交界，位于相邻内含子；
(3)该sgRNA在SLA-3基因上的靶序列是唯一的。
作为本发明的优选方案，上述靶序列为序列表中SEQ ID NO：1～115中任一条序列所示的序列。
作为本发明的优选方案，上述靶序列为序列表中SEQ ID NO：4、5或12所示的序列。
根据本发明的第二方面，本发明提供CRISPR-Cas9特异性敲除猪SLA-3基因的方法，该方法包括如下步骤：
(1)在第一方面所述的sgRNA的靶序列的5’-端加上用于形成粘性末端的序列，合成得到正向寡核苷酸序列；在第一方面所述的sgRNA的靶序列对应的互补序列的两端加上合适的用于形成粘性末端的序列，合成得到反向寡核苷酸序列；将合成的正向寡核苷酸序列与反向寡核苷酸序列退火、复性，形成具有粘性末端的双链寡聚核苷酸；
(2)将上述双链寡聚核苷酸连入线性化的携带Cas9基因的表达载体，得到携带含相应靶序列的sgRNA寡聚核苷酸和Cas9基因的表达载体，转化感受态细菌，筛选鉴定出正确的阳性克隆，并对阳性克隆摇菌、提取质粒；
(3)用上述携带有sgRNA寡聚核苷酸和Cas9基因的表达载体、包装质粒和包装细胞系包装出同时携带靶向SLA-3基因的sgRNA和Cas9的假型慢病毒；
(4)使用上述假型慢病毒感染目的细胞，并进一步培养；然后收集被感染的目的细胞，以其基因组DNA为模板扩增包含上述靶序列的基因片段，经过变性、复性及酶切，确定SLA-3基因的敲除情况。
作为本发明的优选方案，上述表达载体为序列表中SEQ ID NO：116所示序列的载体。
作为本发明的优选方案，上述方法包括如下步骤：
(1)在第一方面所述的sgRNA的靶序列的5’-端加上CACCG序列，合成得到正向寡核苷酸序列；在第一方面所述的sgRNA的靶序列对应的互补序列的5’-端加上AAAC序列、3’-端加上C，合成得到反向寡核苷酸序列；将合成的正向寡核苷酸序列与反向寡核苷酸序列退火、复性，形成具有粘性末端的双链寡聚核苷酸；
(2)将上述双链寡聚核苷酸连入如序列表中SEQ ID NO：116所示序列的表达载体lentiCRISPR v2经BsmB I限制性内切酶酶切得到的线性化载体，得到携带sgRNA寡聚核苷酸的重组表达载体lentiCRISPR v2-SLA-3，转化感受态细菌，筛选鉴定出正确的阳性克隆，并对阳性克隆摇菌、提取质粒；
(3)用上述表达载体lentiCRISPR v2-SLA-3、包装质粒和包装细胞系包装出同时携带靶向SLA-3基因的sgRNA和Cas9的假型慢病毒；
(4)使用上述CRISPR假型慢病毒感染目的细胞，并进一步培养；然后收集被感染的目的细胞，以其基因组DNA为模板扩增包含上述靶序列的基因片段，经过变性、复性及酶切，确定SLA-3基因的敲除情况。
作为本发明的优选方案，上述包装质粒为质粒pLP1、质粒pLP2和质粒pLP/VSVG；上述包装细胞系为HEK293T细胞。
作为本发明的优选方案，上述目的细胞为猪PIEC细胞。
作为本发明的优选方案，上述以其基因组DNA为模板扩增包含上述靶序列的基因片段，经过变性、复性及酶切，确定SLA-3基因的敲除情况，具体为：
(a)以感染病毒的目的细胞的基因组DNA为模板，用SLA-3基因的上下游引物扩增包含上述sgRNA的靶序列的SLA-3基因片段，同时用相同引物扩增未感染病毒的野生型细胞的基因组DNA；
(b)纯化上述扩增到的SLA-3基因片段，然后将来自感染病毒的目的细胞的SLA-3基因片段与来自野生型细胞的SLA-3基因片段等量混合，加热变性、复性，形成杂交DNA分子；
(c)用Cruiser酶切割复性后的杂交DNA分子；
(d)电泳检测酶切产物，检测靶序列介导的SLA-3基因敲除效果。
根据本发明的第三方面，本发明提供在CRISPR-Cas9特异性敲除猪SLA-3基因的方法中用到的重组表达载体lentiCRISPR v2-SLA-3，该重组表达载体的骨架载体的序列如序列表中SEQ ID NO：116所示；所携带的靶序列如第一方面的sgRNA的靶序列，优选序列表中SEQ ID NO：4、5或12所示的靶序列。
根据本发明的第四方面，本发明提供如第一方面所述的sgRNA或第三方面所述的重组表达载体lentiCRISPR v2-SLA-3在CRISPR-Cas9特异性敲除猪SLA-3基因的方法中的用途。
本发明的针对CRISPR-Cas9特异性敲除猪SLA-3基因，成功地找到特异性靶向SLA-3基因的sgRNA，将本发明的sgRNA用于CRISPR-Cas9特异性敲除猪SLA-3基因的方法中，能够快速、精确、高效、特异性地敲除猪SLA-3基因，有效地解决构建SLA-3基因敲除猪周期长和成本高的技术问题。
附图说明
图1为本发明实施例中使用的载体质粒lentiCRISPR v2的质粒图谱；
图2为本发明实施例中使用的包装质粒pLP1的质粒图谱；
图3为本发明实施例中使用的包装质粒pLP2的质粒图谱；
图4为本发明实施例中使用的包装质粒pLP/VSVG的质粒图谱；
图5为本发明实施例中酶切验证靶序列的基因敲除效果的电泳检测结果图，其中M表示DNA Marker，4、5和12分别表示表1中第4号、第5号和第12号靶序列对SLA-3基因的靶向切割效果，WT表示未经过病毒感染和Cas9切割的野生型细胞的PCR产物Cruiser酶切检测结果，箭头处表示经Cruiser酶切割得到的小片段。
具体实施方式
下面结合附图和具体实施例对本发明的技术方案做进一步说明。这些附图和具体实施例不用来限制本发明的范围。若未特别指明，实施例中所用的技术手段为本领域技术人员所熟知的常规手段，所用原料均为市售商品。
以下实施例中涉及的试验材料和试剂：lentiCRISPR v2质粒购自Addgene公司，包装质粒pLP1、pLP2和pLP/VSVG购自Invitrogen公司，包装细胞系HEK293T细胞购自美国模式培养物集存库(ATCC)，PIEC细胞购自中国科学院细胞库，DMEM培养基、Opti-MEM培养基和胎牛血清FBS购自Gibco公司，Lipofectamine 2000购自Invitrogen公司。
以下实施例中未作具体说明的分子生物学实验方法，均参照《分子克隆实验指南》(第三版)J.萨姆布鲁克一书中描述的具体方法进行，或者按照试剂盒和产品说明书进行。
本发明的概括性的技术方案包括以下五个部分：
一、Sus scrofa(猪)SLA-3基因sgRNA靶序列的选择和设计
1.SLA-3基因的sgRNA靶序列选择：
在SLA-3基因外显子区寻找合适的20bp寡核苷酸序列作为靶序列。
2.SLA-3基因的sgRNA靶序列设计：
将上述靶序列及互补序列分别添加接头，形成正向寡核苷酸序列和反向寡核苷酸序列。
二、构建SLA-3基因的CRISPR载体
1.合成上述正向寡核苷酸序列和反向寡核苷酸序列，复性形成具有粘性末端的双链DNA片段(即双链靶序列寡聚核苷酸)。
2.构建CRISPR-sgRNA表达载体：
将上述双链DNA片段构建至目标载体(如lentiCRISPR v2，其质粒图谱如图1所示)，形成如lentiCRISPR v2-SLA-3的慢病毒CRISPR载体。
三、获得表达SLA-3 sgRNA的假型慢病毒
利用包装质粒、包装细胞系与慢病毒CRISPR载体生产表达SLA-3 sgRNA的CRISPR假型慢病毒。
四、感染目的细胞并检测SLA-3基因敲除效果
1.慢病毒感染目的细胞：
将如lentiCRISPR v2-SLA-3的假型慢病毒加入目的细胞培养基进行感染并进一步培养。
2.检测SLA-3基因敲除效果：
收集目的细胞，以基因组DNA为模板扩增包含靶序列的基因片段，经过变性、复性及酶切，确定SLA-3基因的敲除情况。
五、SLA-3基因敲除单克隆的挑选和鉴定
1.对于有确定敲除效果的目的细胞群，通过稀释和单克隆培养，分离出若干单细胞来源的细胞株。
2.鉴定单克隆的SLA-3敲除情况。
以下通过实施例详细说明本发明的技术方案及其有益效果。
实施例一、Sus scrofa(猪)SLA-3基因sgRNA靶序列的选择和设计
靶序列决定了sgRNA的靶向特异性和诱导Cas9切割目的基因的效率。因此，高效特异的靶序列选择和设计是构建sgRNA表达载体的前提。
1.SLA-3基因的sgRNA靶序列选择
针对SLA-3基因，在靶序列选择上应该遵循下列原则：
(1)在SLA-3基因外显子编码区寻找符合5’-N(20)NGG-3’规则的靶序列，其中N(20)表示20个连续的碱基，其中每个N表示A或T或C或G，符合规则的靶序列可以位于正义链或反义链；
(2)选择靠近N端的5个外显子编码区序列，这样的编码区序列的切割会造成SLA-3基因的功能敲除，残留截短的序列不会形成有功能的蛋白；
(3)如果存在多种剪切体，则在共有外显子编码区进行选择，针对SLA-3基因选择靠近N端的5个外显子编码区序列即可满足该条件；
(4)利用在线序列分析工具(http://crispr.mit.edu/)分析以上靶序列在猪基因组中的同源情况，舍弃存在显著同源序列的靶序列，根据评分进一步挑选， 所挑选的靶序列在SLA-3基因上是唯一的。
基于以上原则，选择出表1所示的靶序列集合。
表1 靶序列集合
Figure PCTCN2015081229-appb-000001
Figure PCTCN2015081229-appb-000002
Figure PCTCN2015081229-appb-000003
Figure PCTCN2015081229-appb-000004
2.SLA-3基因的sgRNA靶序列设计：
(1)以lentiCRISPR v2质粒作为表达载体，根据lentiCRISPR v2质粒的特点，在上述N(20)靶序列的5’-端添加CACCG序列，形成正向寡核苷酸序列：
5’-CACCGNNNNNNNNNNNNNNNNNNNN-3’；
(2)在上述N(20)靶序列的反向互补序列的两端添加序列，形成反向寡核苷酸序列：
5’-AAACNNNNNNNNNNNNNNNNNNNNC-3’；
正向寡核苷酸序列和反向寡核苷酸序列可以互补形成具有粘性末端的双链DNA片段：
5’-CACCGNNNNNNNNNNNNNNNNNNNN-3’
3’-CNNNNNNNNNNNNNNNNNNNNCAAA-5’。
实施例二、构建SLA-3基因的sgRNA表达载体
1.合成DNA插入片段
(1)合成上述设计的正向和反向寡核苷酸序列
寡核苷酸序列可以由商业化的公司(如Invitrogen公司)根据提供的序列具体合成。本实施例及以下实施例研究了表1中所列的第4号、第5号和第12号序列所示的靶序列对SLA-3基因的敲除效果。
第4号靶序列对应的正向寡核苷酸序列和反向寡核苷酸序列如下：
5’-CACCGGGCCCTGACTGGTACCCGGG-3’(SEQ ID NO：117)；
5’-AAACCCCGGGTACCAGTCAGGGCCC-3’(SEQ ID NO：118)。
第5号靶序列对应的正向寡核苷酸序列和反向寡核苷酸序列如下：
5’-CACCGGCCCTGACTGGTACCCGGGA-3’(SEQ ID NO：119)；
5’-AAACTCCCGGGTACCAGTCAGGGCC-3’(SEQ ID NO：120)。
第12号靶序列对应的正向寡核苷酸序列和反向寡核苷酸序列如下：
5’-CACCG CCTGGCCCTGACTGGTACCC-3’(SEQ ID NO：121)；
5’-AAACGGGTACCAGTCAGGGCCAGGC-3’(SEQ ID NO：122)。
将对应的正向和反向寡核苷酸序列退火、复性，形成具有粘性末端的双链DNA片段。
反应体系(20μL)如下所示：
正向寡核苷酸(10μM)：1μL
反向寡核苷酸(10μM)：1μL
10×PCR buffer：2μL
ddH2O：16μL
将上述反应体系放入PCR仪，并按以下程序进行反应。
反应程序：
95℃,5min；
80℃,5min；
70℃,5min；
60℃,5min；
50℃,5min；
自然降至室温。
2.构建sgRNA表达载体
(1)利用BsmB I限制性内切酶酶切目标载体lentiCRISPR v2质粒(其序列如序列表中SEQ ID NO：116所示)。
按照以下反应体系进行配制：
LentiCRISPR v2质粒：1μg
10×酶切buffer：2μL
BsmB I限制性内切酶：2μL
补充ddH2O至总体积20μL
将酶切反应体系置于37℃反应4h。
(2)电泳分离并纯化载体片段
酶切结束后，将酶切混合物通过琼脂糖凝胶电泳进行分离，选择载体片段(约12kb)进行切割，并通过DNA凝胶回收柱进行回收。
(3)将合成的双链DNA片段与载体主片段进行连接并转化大肠杆菌
将复性得到的双链DNA片段与回收得到的载体片段进行连接反应，按照以下反应体系进行配制：
LentiCRISPR v2载体片段：100ng
双链DNA片段：200ng
T4连接酶：1μL
T4连接反应buffer：1μL
补充ddH2O至总体积10μL
将连接混合物置于25℃反应2h。
反应结束后将连接混合物转化大肠杆菌DH5α菌株：向连接混合物中加入100μL大肠杆菌DH5α感受态细胞，冰上孵育30min；将混合物放入42℃水浴，热激90s后放入冰上冷却；向混合物加入100μL LB培养基，37℃摇床培养20min； 将混合物涂Amp LB平板，37℃培养14h。
(4)鉴定正确的转化克隆
从Amp LB平板上挑选若干菌落进行扩大培养，提取质粒进行酶切鉴定。挑选可能正确的克隆进行测序，验证插入序列是否正确。对于正确的lentiCRISPR v2-SLA-3载体克隆进行保种。
实施例三、获得表达SLA-3sgRNA的假型慢病毒
1.材料准备
扩增并抽提包装质粒pLP1、pLP2和pLP/VSVG(购自Invitrogen，其图谱分别如图2、图3和图4所示)；扩增并抽提载体质粒lentiCRISPR v2-SLA-3；培养包装细胞系HEK293T细胞(购自ATCC)；DMEM培养基、Opti-MEM培养基和胎牛血清FBS(购自Gibco)；Lipofectamine2000(购自Invitrogen)；HEK293T细胞培养于含5％CO2的37℃培养环境中，培养基为含10％FBS的DMEM培养基。
2.转染和病毒包装
第一天：将包装细胞系HEK293T传代至10cm dish，约30％融合度；
第二天：在HEK293T达到80％融合度时按照下列配方进行转染：
配制混合物1，包含：
lentiCRISPR v2-SLA-3：6μg
pLP1：6μg
pLP2：6μg
pLP/VSVG：3μg
Opti-MEM：500μL。
配制混合物2，包含：
Lipofectamine 2000：30μL
Opti-MEM：500μL。
静置5min后，将混合物1和混合物2混匀成转染混合物，静置20min。
将HEK293T培养基换为无血清DMEM培养基，加入转染混合物，37℃培养8h后换为20％FBS的DMEM培养基，继续培养。
3.病毒收集与保存
第三天：转染48h后收集含病毒的HEK293T培养基上清，用0.45μm滤头过滤后，分装，放置-80℃保存。
实施例四、感染目的细胞并检测靶序列的敲除效果
1.材料准备
培养目的细胞系猪髋动脉血管内皮细胞PIEC(购自中国科学院细胞库)；DMEM培养基和胎牛血清FBS(购自Gibco)；不同靶序列(序列4、序列5和序列12)的lentiCRISPR v2-SLA-3假型慢病毒；PIEC细胞培养于含5％CO2的37℃培养环境中，培养基为含10％FBS的DMEM培养基。
2.慢病毒感染目的细胞
第一天：将目的细胞传代至6孔板，约20％融合密度。每一种病毒需要一个6孔，同时需要效率对照一个6孔。
第二天：待目的细胞约40％融合密度时加入1mL lentiCRISPR v2-SLA-3假型慢病毒上清及1mL DMEM培养基。效率对照不需要添加慢病毒。
第三天：感染24h后去除含病毒培养基，换成正常培养基，加入嘌呤霉素至终浓度2μg/mL，没有感染病毒的效率对照样品也同时加入嘌呤霉素作为对照，培养48h。
3.细胞感染效率检测和培养
第五天：未感染的效率对照细胞在嘌呤霉素的作用下应该全部凋亡(>95％)。根据感染慢病毒细胞的凋亡情况判断细胞的感染效率，通常可以达到90％以上的感染效率(凋亡率<10％)。必要时可以将病毒上清进行浓缩或梯度稀释后进行感染以达到合适的感染效率。
经过嘌呤霉素筛选后，未感染的细胞发生凋亡。将目的细胞重新传代并换为普通培养基培养48h。
4.检测SLA-3基因敲除效果
(1)设计上下游引物以扩增SLA-3基因片段，其中上下游引物序列如下所示：
CTCGGGGTCTCAGGCTCCAGGGCGG(SEQ ID NO：123)
GGGCAGGAAACAAGGGAGGG(SEQ ID NO：124)。
目的扩增片段包含sgRNA靶序列，大小为487bp。靶序列至片段两端的位置不少于100bp。
(2)收集部分目的细胞，使用promega基因组DNA试剂盒抽提基因组DNA。同时抽提野生型目的细胞的基因组DNA。
(3)以基因组DNA为模板扩增包含靶序列的SLA-3基因片段(包括感染 的突变样品和野生型样品)。
扩增反应体系(20μL)如下：
上游引物(10μM)：1μL
下游引物(10μM)：1μL
2×PCR Mix：10μL
基因组DNA：100ng
以上述反应体系进行配制，放入PCR仪，并按下列程序进行反应。
反应程序：
95℃,3min
95℃,30s
58℃,20s
72℃,20s
72℃,3min；
其中第二步至第四步重复35个循环。
(4)电泳检测PCR产物并回收纯化
(5)将纯化后的DNA片段分别加热变性、复性，形成杂交DNA分子(包括突变样品和野生型样品)。
反应体系如下所示：
基因组PCR片段：200ng
5×反应buffer：2μL
反应体系共9μL
以上述反应体系进行配制，放入PCR仪，并按下列程序进行反应。
反应程序：
95℃,5min；
80℃,5min；
70℃,5min；
60℃,5min；
50℃,5min；
自然降至室温。
(6)用Cruiser酶切割复性后的杂交DNA(包括突变样品和野生型样品)向经过变性、复性的反应混合物加入1μL Cruiser酶，45℃孵育20min。
(7)电泳检测酶切产物，检测靶序列介导的SLA-3基因敲除效果。
将经过酶切的DNA片段用2％的琼脂糖凝胶进行电泳分析，100V，25min。确定目的片段的切割情况，判断靶序列的基因敲除效果。
对突变DNA的切割识别基于以下原理：经过感染的细胞会表达sgRNA和Cas9。基因组DNA如果被sgRNA介导的Cas9蛋白靶向切割，经过修复后会在切割位点附近引入突变(野生型变为突变型)。由于野生型和突变型序列在该位置不匹配，以此为模板扩增出的野生型DNA与突变型DNA经过变复性形成的杂交分子会就产生局部的环形(loop)结构。而后者可以被Cruiser酶识别并切断，导致杂交DNA分子被切割成小片段。
结果如图5所示，未经过病毒感染的野生型细胞的PCR产物未检测到小片段；而序列4、序列5和序列12能够有效靶向SLA-3基因产生切割，因此检测到小片段的存在，表明序列4、序列5和序列12能够作为CRISPR-Cas9特异性敲除猪SLA-3基因的靶序列。
实施例五、SLA-3基因敲除单克隆的挑选和鉴定
1.单克隆的挑选(基于序列4、序列5和序列12的靶序列)
(1)将部分感染的目的细胞群进行传代，取100个单细胞转移至10cm dish培养。
(2)培养约10天后，有相当数量的单克隆生长到肉眼可见的水平。
(3)用移液器头刮取独立的克隆，将细胞转移至24孔板中培养，每个孔对应一个克隆。
(4)再经过约一周的培养后，有部分克隆长至足够的数量，准备做进一步的鉴定。
2.鉴定单克隆的SLA-3敲除情况
(1)收集待检的单克隆及野生型细胞，分别抽提基因组DNA。
(2)按照前述方法，分别扩增单克隆及野生型细胞的SLA-3基因片段，所扩增的基因片段包含sgRNA靶序列。
(3)将等量的单克隆PCR片段与野生型PCR片段混合，加热变性、复性，形成杂交DNA分子。
(4)用Cruiser酶切割退火后的杂交DNA，45℃孵育20min。
(5)电泳检测酶切产物，根据是否有切割片段确定单克隆是否发生有效突变。
结果显示，基于序列4所示的靶序列的lentiCRISPR v2-SLA-3假型慢病毒感染目的细胞，从100个单细胞中随机挑选的20个单克隆经Cruiser酶酶切电泳检测，其中有17个单克隆能检测到切割小片段，表明基因敲除发生，基因敲除效率能够达到85％以上，说明序列4所示的靶序列具有很高的靶向敲除SLA-3基因的作用。基于序列5所示的靶序列的lentiCRISPR v2-SLA-3假型慢病毒感染目的细胞，从100个单细胞中随机挑选的20个单克隆经Cruiser酶酶切电泳检测，其中有19个单克隆能检测到切割小片段，表明基因敲除发生，基因敲除效率能够达到95％以上，说明序列5所示的靶序列具有很高的靶向敲除SLA-3基因的作用。基于序列12所示的靶序列的lentiCRISPR v2-SLA-3假型慢病毒感染目的细胞，从100个单细胞中随机挑选的20个单克隆经Cruiser酶酶切电泳检测，其中有18个单克隆能检测到切割小片段，表明基因敲除发生，基因敲除效率能够达到90％以上，说明序列12所示的靶序列具有很高的靶向敲除SLA-3基因的作用。
以上内容是结合具体的实施方式对本发明所作的进一步详细说明，不能认定本发明的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说，在不脱离本发明构思的前提下，还可以做出若干简单推演或替换。

Claims (10)

  1. 在CRISPR-Cas9特异性敲除猪SLA-3基因中用于特异性靶向SLA-3基因的sgRNA，其特征在于：
    (1)所述sgRNA在SLA-3基因上的靶序列符合5’-N(20)NGG-3’的序列排列规则，其中N(20)表示20个连续的碱基，其中每个N表示A或T或C或G，符合规则的靶序列可以位于正义链或反义链；
    (2)所述sgRNA在SLA-3基因上的靶序列位于SLA-3基因的N端的5个外显子编码区，或序列的主要部分位于SLA-3基因的N端的5个外显子，其余部分跨越与相邻内含子的交界，位于相邻内含子；
    (3)所述sgRNA在SLA-3基因上的靶序列是唯一的。
  2. 根据权利要求1所述的用于特异性靶向SLA-3基因的sgRNA，其特征在于，所述靶序列为序列表中SEQ ID NO：1～115中任一条序列所示的序列。
  3. 根据权利要求1所述的用于特异性靶向SLA-3基因的sgRNA，其特征在于，所述靶序列为序列表中SEQ ID NO：4、5或12所示的序列。
  4. CRISPR-Cas9特异性敲除猪SLA-3基因的方法，其特征在于，所述方法包括如下步骤：
    (1)在权利要求1-3任一项所述的sgRNA的靶序列的5’-端加上用于形成粘性末端的序列，合成得到正向寡核苷酸序列；在权利要求1-3任一项所述的sgRNA的靶序列对应的互补序列的两端加上合适的用于形成粘性末端的序列，合成得到反向寡核苷酸序列；将合成的所述正向寡核苷酸序列与反向寡核苷酸序列退火、复性，形成具有粘性末端的双链寡聚核苷酸；
    (2)将所述双链寡聚核苷酸连入线性化的携带Cas9基因的表达载体，得到携带含相应靶序列的sgRNA寡聚核苷酸和Cas9基因的表达载体，转化感受态细菌，筛选鉴定出正确的阳性克隆，并对所述阳性克隆摇菌、提取质粒；
    (3)用所述携带有sgRNA寡聚核苷酸和Cas9基因的表达载体、包装质粒和包装细胞系包装出同时携带靶向SLA-3基因的sgRNA和Cas9的假型慢病毒；
    (4)使用所述假型慢病毒感染目的细胞，并进一步培养；然后收集被感染的目的细胞，以其基因组DNA为模板扩增包含所述靶序列的基因片段，经过变性、复性及酶切，确定SLA-3基因的敲除情况。
  5. 根据权利要求4所述的CRISPR-Cas9特异性敲除猪SLA-3基因的方法，其特征在于，所述表达载体为序列表中SEQ ID NO：116所示序列的载体。
  6. 根据权利要求4或5所述的CRISPR-Cas9特异性敲除猪SLA-3基因的方 法，其特征在于，所述方法包括如下步骤：
    (1)在权利要求1-3任一项所述的sgRNA的靶序列的5’-端加上CACCG序列，合成得到正向寡核苷酸序列；在权利要求1-3任一项所述的sgRNA的靶序列对应的互补序列的5’-端加上AAAC序列、3’-端加上C，合成得到反向寡核苷酸序列；将合成的所述正向寡核苷酸序列与反向寡核苷酸序列退火、复性，形成具有粘性末端的双链寡聚核苷酸；
    (2)将所述双链寡聚核苷酸连入如序列表中SEQ ID NO：116所示序列的表达载体lentiCRISPR v2经BsmB I限制性内切酶酶切得到的线性化载体，得到携带sgRNA寡聚核苷酸的重组表达载体lentiCRISPR v2-SLA-3，转化感受态细菌，筛选鉴定出正确的阳性克隆，并对所述阳性克隆摇菌、提取质粒；
    (3)用所述表达载体lentiCRISPR v2-SLA-3、包装质粒和包装细胞系包装出同时携带靶向SLA-3基因的sgRNA和Cas9的假型慢病毒；
    (4)使用所述假型慢病毒感染目的细胞，并进一步培养；然后收集被感染的目的细胞，以其基因组DNA为模板扩增包含所述靶序列的基因片段，经过变性、复性及酶切，确定SLA-3基因的敲除情况。
  7. 根据权利要求6所述的CRISPR-Cas9特异性敲除猪SLA-3基因的方法，其特征在于，所述包装质粒为质粒pLP1、质粒pLP2和质粒pLP/VSVG；所述包装细胞系为HEK293T细胞。
  8. 根据权利要求6所述的CRISPR-Cas9特异性敲除猪SLA-3基因的方法，其特征在于，所述目的细胞为猪PIEC细胞；
    所述以其基因组DNA为模板扩增包含所述靶序列的基因片段，经过变性、复性及酶切，确定SLA-3基因的敲除情况，具体为：
    (a)以感染病毒的目的细胞的基因组DNA为模板，用SLA-3基因的上下游引物扩增包含所述sgRNA的靶序列的SLA-3基因片段，同时用相同引物扩增未感染病毒的野生型细胞的基因组DNA；
    (b)纯化上述扩增到的SLA-3基因片段，然后将来自感染病毒的目的细胞的SLA-3基因片段与来自野生型细胞的SLA-3基因片段等量混合、加热变性、复性，形成杂交DNA分子；
    (c)用Cruiser酶切割复性后的杂交DNA分子；
    (d)电泳检测酶切产物，检测靶序列介导的SLA-3基因敲除效果。
  9. 在CRISPR-Cas9特异性敲除猪SLA-3基因的方法中用到的重组表达载体 lentiCRISPR v2-SLA-3，其特征在于，所述重组表达载体的骨架载体的序列如序列表中SEQ ID NO：116所示；所携带的靶序列如权利要求1-3任一项所述的sgRNA的靶序列，优选序列表中SEQ ID NO：4、5或12所示的靶序列。
  10. 如权利要求1-3任一项所述的sgRNA或权利要求9所述的重组表达载体lentiCRISPR v2-SLA-3在CRISPR-Cas9特异性敲除猪SLA-3基因的方法中的用途。
PCT/CN2015/081229 2015-06-11 2015-06-11 CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA WO2016197357A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2015/081229 WO2016197357A1 (zh) 2015-06-11 2015-06-11 CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA
CN201580000474.9A CN106414740A (zh) 2015-06-11 2015-06-11 CRISPR‑Cas9特异性敲除猪SLA‑3基因的方法及用于特异性靶向SLA‑3基因的sgRNA

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/081229 WO2016197357A1 (zh) 2015-06-11 2015-06-11 CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA

Publications (1)

Publication Number Publication Date
WO2016197357A1 true WO2016197357A1 (zh) 2016-12-15

Family

ID=57502928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/081229 WO2016197357A1 (zh) 2015-06-11 2015-06-11 CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA

Country Status (2)

Country Link
CN (1) CN106414740A (zh)
WO (1) WO2016197357A1 (zh)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108373997B (zh) * 2018-02-08 2020-10-27 西北农林科技大学 一种pMKRN1基因敲除的猪体细胞及其制备方法和应用
CN109280643B (zh) * 2018-09-30 2020-11-06 北京鼎成肽源生物技术有限公司 一种rfft细胞
CN110172505A (zh) * 2019-04-23 2019-08-27 中国农业大学 Trim33基因作为prrsv感染相关因子的应用
CN111041027B (zh) * 2019-12-19 2022-10-28 广东省农业科学院动物卫生研究所 一种Atg12基因敲除细胞系构建方法及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104480144A (zh) * 2014-12-12 2015-04-01 武汉大学 用于艾滋病基因治疗的CRISPR/Cas9重组慢病毒载体及其慢病毒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105567738A (zh) * 2016-01-18 2016-05-11 南开大学 使用基因组编辑技术CRISPR-Cas9诱导CCR5Δ32缺失的方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104480144A (zh) * 2014-12-12 2015-04-01 武汉大学 用于艾滋病基因治疗的CRISPR/Cas9重组慢病毒载体及其慢病毒

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU, ZHIGUO ET AL.: "Research progress on CRISPR/Cas9 mediated genome editing", ACTA VETERINARIA ET ZOOTECHNICA SINICA, vol. 45, no. 10, 22 October 2014 (2014-10-22), pages 1567 - 1583, ISSN: 0366-6964 *
LUZ M. REYES ET AL.: "Creating class I MHC-Null pigs using guide RNA and the Cas9 endonuclease", THE JOURNAL OF IMMUNOLOGY, vol. 193, 22 October 2014 (2014-10-22), pages 5751 - 5757, XP055298518, ISSN: 1550-6606 *

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006520B2 (en) 2011-07-22 2024-06-11 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10508298B2 (en) 2013-08-09 2019-12-17 President And Fellows Of Harvard College Methods for identifying a target site of a CAS9 nuclease
US11920181B2 (en) 2013-08-09 2024-03-05 President And Fellows Of Harvard College Nuclease profiling system
US10954548B2 (en) 2013-08-09 2021-03-23 President And Fellows Of Harvard College Nuclease profiling system
US11046948B2 (en) 2013-08-22 2021-06-29 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9999671B2 (en) 2013-09-06 2018-06-19 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US10597679B2 (en) 2013-09-06 2020-03-24 President And Fellows Of Harvard College Switchable Cas9 nucleases and uses thereof
US10682410B2 (en) 2013-09-06 2020-06-16 President And Fellows Of Harvard College Delivery system for functional nucleases
US11299755B2 (en) 2013-09-06 2022-04-12 President And Fellows Of Harvard College Switchable CAS9 nucleases and uses thereof
US10858639B2 (en) 2013-09-06 2020-12-08 President And Fellows Of Harvard College CAS9 variants and uses thereof
US10912833B2 (en) 2013-09-06 2021-02-09 President And Fellows Of Harvard College Delivery of negatively charged proteins using cationic lipids
US11124782B2 (en) 2013-12-12 2021-09-21 President And Fellows Of Harvard College Cas variants for gene editing
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
US10465176B2 (en) 2013-12-12 2019-11-05 President And Fellows Of Harvard College Cas variants for gene editing
US11578343B2 (en) 2014-07-30 2023-02-14 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US10704062B2 (en) 2014-07-30 2020-07-07 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
US11214780B2 (en) 2015-10-23 2022-01-04 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US12043852B2 (en) 2015-10-23 2024-07-23 President And Fellows Of Harvard College Evolved Cas9 proteins for gene editing
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
US10947530B2 (en) 2016-08-03 2021-03-16 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11999947B2 (en) 2016-08-03 2024-06-04 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11702651B2 (en) 2016-08-03 2023-07-18 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US10113163B2 (en) 2016-08-03 2018-10-30 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US12084663B2 (en) 2016-08-24 2024-09-10 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306324B2 (en) 2016-10-14 2022-04-19 President And Fellows Of Harvard College AAV delivery of nucleobase editors
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US11820969B2 (en) 2016-12-23 2023-11-21 President And Fellows Of Harvard College Editing of CCR2 receptor gene to protect against HIV infection
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
US12058986B2 (en) 2017-04-20 2024-08-13 Egenesis, Inc. Method for generating a genetically modified pig with inactivated porcine endogenous retrovirus (PERV) elements
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11932884B2 (en) 2017-08-30 2024-03-19 President And Fellows Of Harvard College High efficiency base editors comprising Gam
US11795443B2 (en) 2017-10-16 2023-10-24 The Broad Institute, Inc. Uses of adenosine base editors
US11795452B2 (en) 2019-03-19 2023-10-24 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11643652B2 (en) 2019-03-19 2023-05-09 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11447770B1 (en) 2019-03-19 2022-09-20 The Broad Institute, Inc. Methods and compositions for prime editing nucleotide sequences
US11912985B2 (en) 2020-05-08 2024-02-27 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
US12031126B2 (en) 2020-05-08 2024-07-09 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence

Also Published As

Publication number Publication date
CN106414740A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
WO2016197357A1 (zh) CRISPR-Cas9特异性敲除猪SLA-3基因的方法及用于特异性靶向SLA-3基因的sgRNA
WO2016197356A1 (zh) CRISPR-Cas9特异性敲除猪SLA-2基因的方法及用于特异性靶向SLA-2基因的sgRNA
WO2016187904A1 (zh) CRISPR-Cas9特异性敲除猪CMAH基因的方法及用于特异性靶向CMAH基因的sgRNA
WO2016197355A1 (zh) CRISPR-Cas9特异性敲除猪SALL1基因的方法及用于特异性靶向SALL1基因的sgRNA
WO2016197358A1 (zh) CRISPR-Cas9特异性敲除猪FGL2基因的方法及用于特异性靶向FGL2基因的sgRNA
WO2016197354A1 (zh) CRISPR-Cas9特异性敲除猪PDX1基因的方法及用于特异性靶向PDX1基因的sgRNA
WO2016197361A1 (zh) CRISPR-Cas9特异性敲除猪GGTA1基因的方法及用于特异性靶向GGTA1基因的sgRNA
WO2016197362A1 (zh) CRISPR-Cas9特异性敲除猪vWF基因的方法及用于特异性靶向vWF基因的sgRNA
WO2016197360A1 (zh) CRISPR-Cas9特异性敲除猪GFRA1基因的方法及用于特异性靶向GFRA1基因的sgRNA
WO2016197359A1 (zh) CRISPR-Cas9特异性敲除猪SLA-1基因的方法及用于特异性靶向SLA-1基因的sgRNA
CN105518135B (zh) CRISPR-Cas9特异性敲除猪CMAH基因的方法及用于特异性靶向CMAH基因的sgRNA
KR102553518B1 (ko) Hiv 감염의 rna-가이드된 치료를 위한 방법 및 조성물
CN107502608B (zh) 用于敲除人ALDH2基因的sgRNA、ALDH2基因缺失细胞株的构建方法及应用
US10988777B2 (en) Method for inducing CCR5Δ32 deletion by using CRISPR-Cas9 genome editing technique
CN104480144B (zh) 用于艾滋病基因治疗的CRISPR/Cas9重组慢病毒载体及其慢病毒
CN111172114A (zh) 一种人源化肠癌前病变永生化上皮细胞系、构建方法及其应用
CN106987560A (zh) Rk‑13细胞hb基因敲除稳定株的构建方法
JP2023547887A (ja) セーフハーバー遺伝子座
CN112979823B (zh) 一种用于治疗和/或预防β血红蛋白病的产品及融合蛋白
JP2023508400A (ja) 遺伝子発現を増強させる哺乳動物配列への標的組込み
US20220364072A1 (en) Fusion protein that improves gene editing efficiency and application thereof
US20230167431A1 (en) Tagged gene editing technology for clinical cell sorting and enrichment
Rousseau Engineering Virus-Like Particles for the Delivery of Genome Editing Enzymes
WO2020029171A1 (zh) 无内源hla基因背景的抗原递呈细胞系的构建方法、抗原递呈细胞系及其用途
WO2022109275A2 (en) Vectors, systems and methods for eukaryotic gene editing

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15894627

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15894627

Country of ref document: EP

Kind code of ref document: A1